<DOC>
	<DOCNO>NCT02526420</DOCNO>
	<brief_summary>A Phase 2 , open-label dose-finding safety study individualize monthly VRS-317 dose five month adult GHD .</brief_summary>
	<brief_title>Versartis International Trial Adults With Long-Acting Growth Hormone</brief_title>
	<detailed_description>A Phase 2 , dose find safety study evaluate individualize monthly VRS-317 dose regimen adult GHD . This open-label , international , multicenter study VRS-317 treatment five month . This treatment period include monthly dose titration subject 's mean IGF-I SDS value within target range two consecutive month . Subjects stratify three cohort base sensitivity rhGH .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Female subject childbearing potential must negative pregnancy test use appropriate contraceptive method Subjects must document GHD adulthood . Subjects take hormone replacement therapy must stable course treatment least 3 month . Subjects underlie disorder responsible subject 's GHD must clinically stable least 6 month . Subjects receive daily rhGH injection must washout 14 day . Subjects must provide sign informed consent . Subjects must BMI ( kg/m2 ) 19.0 35.0 . Subjects diabetes mellitus inadequate glucose control Subjects untreated adrenal insufficiency . Subjects free thyroxine outside normal reference range . Subjects currently take oral glucocorticoid , except physiological maintenance dose oral glucocorticoid subject multiple pituitary hormone deficiency . Subjects current significant cardiovascular disease , heart insufficiency NYHA class &gt; 2 . Subjects current significant cerebrovascular , pulmonary , neurological , renal , inflammatory , hepatobiliary disease . Subjects current papilledema . Subjects history persistent recur migraine . Subjects current edema ( â‰¥ CTCAE Grade 2 ) . Subjects current drug alcohol abuse . Subjects document history HIV , current HBV HCV infection Subjects prior history malignancy exclude adequately treat nonmelanoma skin cancer situ carcinoma cervix . Women pregnant breastfeeding . Subjects significant abnormality Screening laboratory result</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>VRS-317</keyword>
	<keyword>Long Acting Growth Hormone</keyword>
	<keyword>Versartis</keyword>
	<keyword>somavaratan</keyword>
	<keyword>Growth Hormone Deficiency</keyword>
	<keyword>Adult Growth Hormone Deficiency</keyword>
	<keyword>AGHD</keyword>
	<keyword>Growth Hormone Replacement</keyword>
	<keyword>Growth Hormone Replacement Therapy</keyword>
	<keyword>XTEN</keyword>
</DOC>